Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06312787 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT06312787 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 15 participants.
The verdict
NCT06312787, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability, effect of food on the pharmacokinetic parameters, and safety and tolerability, of a tablet formulation of VX-118 in healthy participants.
Interventions
- DRUG VX-118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2024-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06312787
The ClinicalTrials.gov registry entry for NCT06312787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-118 is the first listed.
NCT06312787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06312787 about?
NCT06312787 is a clinical study titled "A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation". The purpose of this study is to evaluate the relative bioavailability, effect of food on the pharmacokinetic parameters, and safety and tolerability, of a tablet formulation of VX-118 in healthy participants.
What is the current status of trial NCT06312787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-04-02. Estimated completion is 2024-05-04.
What interventions are being tested in trial NCT06312787?
The interventions under investigation include: VX-118 (DRUG).
Who is sponsoring clinical trial NCT06312787?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.